Skip to content

Alibaba-Backed Creative Biosciences Weighing Hong Kong IPO

  • Potential listing could raise $200 million as soon as 2022
  • Firm also counts CDH, IDG and China Renaissance among backers
A technician prepares a sample inside a laboratory
Photographer: Anthony Kwan/Bloomberg

Creative Biosciences (Guangzhou) Co., a developer of DNA testing kits for colorectal cancer, is considering an initial public offering in Hong Kong as soon as next year, people with knowledge of the matter said. 

The Chinese firm, backed by Alibaba Group Holding Ltd., has been in discussions with potential advisers about a listing, said the people, who asked not to be identified as the information is private. The prospective IPO could raise about $200 million, the people said.